Changes in tonsillar tissue in early HIV-1 infection and during 3 years of antiretroviral therapyNote

Apmis ◽  
2000 ◽  
Vol 108 (7-8) ◽  
pp. 539-550 ◽  
Author(s):  
PAL VOLTERSVIK ◽  
ANNE MA DYRHOL-RIISE ◽  
LEIF BOSTAD ◽  
BARD I. ROSOK ◽  
JAN OLOFSSON ◽  
...  
Keyword(s):  
2017 ◽  
Vol 3 ◽  
pp. 4
Author(s):  
B. Luttge ◽  
C. Dobrowolski ◽  
M.A. Checkley ◽  
J. Karn

Apmis ◽  
2008 ◽  
Vol 108 (7-8) ◽  
pp. 539-550
Author(s):  
PAL Voltersvik ◽  
ANNE MA Dyrhol-Riise ◽  
LEIF Bostad ◽  
BÅRD I. RØSok ◽  
JAN Olofsson ◽  
...  

2007 ◽  
Vol 88 (1) ◽  
pp. 217-225 ◽  
Author(s):  
Marie Breton ◽  
Chenqi Zhao ◽  
Marc Ouellette ◽  
Michel J. Tremblay ◽  
Barbara Papadopoulou

Live-vector human immunodeficiency virus (HIV) vaccines are an integral part of a number of HIV vaccine regimens currently under evaluation that have yielded promising results in pre-clinical testing. In this report, a non-pathogenic protozoan parasitic vector, Leishmania tarentolae, which shares common target cells with HIV-1, was used to express full-length HIV-1 Gag protein. Immunization of BALB/c mice with recombinant L. tarentolae led to the expansion of HIV-1 Gag-specific T cells and stimulated CD8+ T cells to produce gamma interferon in response to specific viral Gag epitopes. A booster immunization with recombinant L. tarentolae elicited effector memory HIV-1 Gag-specific CD4+ T lymphocytes and increased antibody titres against HIV-1 Gag. Most importantly, immunization of human tonsillar tissue cultured ex vivo with Gag-expressing L. tarentolae vaccine vector elicited a 75 % decrease in virus replication following exposure of the immunized tonsils to HIV-1 infection. These results demonstrated that recombinant L. tarentolae is capable of eliciting effective immune responses in mice and human systems, respectively, and suggest that this novel non-pathogenic recombinant vaccine vector shows excellent promise as a vaccination strategy against HIV-1.


AIDS ◽  
1999 ◽  
Vol 13 (18) ◽  
pp. 2507-2513 ◽  
Author(s):  
Emiliano N. Mugnaini ◽  
Anette M. Syversen ◽  
Mette Sannes ◽  
Atle Freng ◽  
Jan E. Brinchmann

Acta Naturae ◽  
2015 ◽  
Vol 7 (3) ◽  
pp. 113-115
Author(s):  
E. S. Matyugina ◽  
M. S. Novikov ◽  
D. A. Babkov ◽  
V. T. Valuev-Elliston ◽  
C. Vanpouille ◽  
...  

Several 5-aminouracil derivatives that have previously been shown to inhibit Mycobacterium tuberculosis growth at concentrations of 5-40 g/mL are demonstrated to act also as noncompetitive non-nucleoside inhibitors of HIV-1 reverse transcriptase without causing toxicity in vitro (МT-4 cells) and ex vivo (human tonsillar tissue).


Author(s):  
James K. Koehler ◽  
Steven G. Reed ◽  
Joao S. Silva

As part of a larger study involving the co-infection of human monocyte cultures with HIV and protozoan parasites, electron microscopic observations were made on the course of HIV replication and infection in these cells. Although several ultrastructural studies of the cytopathology associated with HIV infection have appeared, few studies have shown the details of virus production in “normal,” human monocytes/macrophages, one of the natural targets of the virus, and suspected of being a locus of quiescent virus during its long latent period. In this report, we detail some of the interactions of developing virons with the membranes and organelles of the monocyte host.Peripheral blood monocytes were prepared from buffy coats (Portland Red Cross) by Percoll gradient centrifugation, followed by adherence to cover slips. 90-95% pure monocytes were cultured in RPMI with 5% non-activated human AB serum for four days and infected with 100 TCID50/ml of HIV-1 for four hours, washed and incubated in fresh medium for 14 days.


1997 ◽  
Vol 23 (3) ◽  
pp. 83-92 ◽  
Author(s):  
D. Seilhean ◽  
A. Dzia-Lepfoundzou ◽  
V. Sazdovitch ◽  
B. Cannella ◽  
C. S. Raine ◽  
...  

2000 ◽  
Vol 14 (2) ◽  
pp. 50-55
Author(s):  
FORTHEPEDIATRICPULMONARYANDCA ◽  
H COHEN ◽  
X CHEN ◽  
S SUNKLE ◽  
L DAVIS ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document